Due to millions of years of coevolution, humans count on our gut bacteria to maintain our health.
Stellate Therapeutics uses the human microbiome as a source of small molecule therapies for devastating diseases, starting with neurological disorders.
Our lead candidate, STL-101 is a potential first-in-class, disease-modifying therapy for Parkinson’s and Alzheimer’s disease.
Nicole McKnight PhD
CEO
Patrice Garnier PhD
President
Patricia Richard PhD
Head of R&D, US
Xavier Manière PharmD, PhD
Head of R&D, Europe
Antoine Danchin PhD
Scientific Founder
Bernard Munos MBA, MS
Robert Schneider PhD
Alexandre Mouradian
Eric Fourmentin
Géraldine Androdias MD
Sahar El Aidy PhD
Michael Spedding PhD